Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY, United States.
Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, United States.
Crit Rev Oncol Hematol. 2017 Dec;120:151-162. doi: 10.1016/j.critrevonc.2017.10.014. Epub 2017 Nov 1.
A systematic review was conducted to illustrate the bleeding risks associated with targeted therapies used in the treatment of metastatic renal cell carcinoma (mRCC). Eligible studies included phase II, III, or IV clinical trials using pazopanib, sunitinib, cabozantinib, lenvatinib, everolimus, temsirolimus, bevacizumab, axitinib, and/or sorafenib in the setting of mRCC. Types of bleeding event(s), bleeding event frequency, and incidence of thrombocytopenia were collected from the relevant articles. ClinicalTrials.gov was also searched for incidence of "Serious bleeding adverse effects" reported in these trials. The incidences of bleeding events ranged from 1 to 36%, and incidences of thrombocytopenia ranged from 2 to 78%. Available serious bleeding adverse events ranged from 1 to 7%. The highest percentage of bleeding incidences were seen with bevacizumab, while the lowest percentage of bleeding incidences were seen with axitinib. All of the included trials were of high quality per Jadad scoring.
一项系统评价旨在阐明转移性肾细胞癌 (mRCC) 治疗中靶向治疗相关的出血风险。纳入的研究包括使用帕唑帕尼、舒尼替尼、卡博替尼、仑伐替尼、依维莫司、替西罗莫司、贝伐珠单抗、阿昔替尼和/或索拉非尼治疗 mRCC 的 II 期、III 期或 IV 期临床试验。从相关文章中收集了出血事件类型、出血事件频率和血小板减少症的发生率。还在 ClinicalTrials.gov 上搜索了这些试验报告的“严重出血不良事件”的发生率。出血事件的发生率为 1%至 36%，血小板减少症的发生率为 2%至 78%。可用的严重出血不良事件发生率为 1%至 7%。贝伐珠单抗的出血发生率最高，阿昔替尼的出血发生率最低。根据 Jadad 评分，所有纳入的试验均为高质量试验。
